SCHEMBL7146014

SCHEMBL7146014

OCC1CCCN(c2ccc(F)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.56
CYP2C19 P33261 1/20 0.56
NOTUM Q6P988 1/20 0.49
NPC1 O15118 3/20 0.45
RAB9A P51151 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
FFAR4 Q5NUL3 1/20 0.43
DEGS1 O15121 1/20 0.43
MAP4K4 O95819 1/20 0.42
TRPA1 O75762 4/20 0.42
DRD2 P14416 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21135466 1.00 CYP3A4 (0.56) CYP3A4CYP2C19NOTUMNPC1RAB9A
SCHEMBL21135575 1.00 CYP3A4 (0.56) CYP3A4CYP2C19NOTUMNPC1RAB9A
SCHEMBL1812978 0.90 NPC1 (0.62) CYP3A4CYP2C19NOTUMNPC1RAB9A
SCHEMBL27714650 0.90 NOTUM (0.55) CYP3A4CYP2C19NOTUMNPC1RAB9A
SCHEMBL25855629 0.85 ESR1 (0.45) CYP3A4CYP2C19MAP4K4JAK2SYK
SCHEMBL1815810 0.85 CYP3A4 (0.44) CYP3A4CYP2C19NOTUMFFAR4DEGS1
SCHEMBL21135496 0.84 NOTUM (0.49) NOTUMALDH1A1MAPTMAPK1MAP4K4
SCHEMBL21135458 0.84 NOTUM (0.49) NOTUMALDH1A1MAPTMAPK1MAP4K4
SCHEMBL7790528 0.84 EPHX2 (0.51) RAB9AMAP4K4JAK2SYKTYMP
SCHEMBL77035 0.84 KDM4E (0.49) CYP3A4CYP2C19NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101974604-A Method for preparing paroxetine intermediate by enzyme resolution in ionic liquid NANJING UNIVERSITY OF TECHNOLOGY 2011-02-16 CN claimed
EP-1246821-A2 PROCESS FOR THE PREPARATION OF PAROXETINE AND SYNTHETIC INTERMEDITATES THEREOF SmithKline Beecham plc (GB) 2002-10-09 EP claimed
WO-2001004113-A2 PROCESS FOR THE PREPARATION OF PAROXETINE AND SYNTHETIC INTERMEDITATES THEREOF SMITHKLINE BEECHAM PLC (GB) 2001-01-18 WO claimed
CN-101360742-A Substituted phenylpiperidines with serotonin-derived activity and enhanced therapeutic properties AUSPEX PHARMACEUTICALS INC (US) 2009-02-04 CN disclosed
US-6521758-B2 Useful in purifying these compounds from the corresponding des-fluoro impurity; making paroxetine SYNTHON BV (NL) 2003-02-18 US disclosed
US-20020082277-A1 Tosylate salts of 4-(p-fluorophenyl)-piperidine -3-carbinols SYNTHON IP INC. 2002-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082277-A1 Tosylate salts of 4-(p-fluorophenyl)-piperidine -3-carbinols HTR3C, HTR5A, HTR3B CYP3A4 162/4885CYP2C19 39/4885NOTUM 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.